A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 6, 2023

Primary Completion Date

May 24, 2024

Study Completion Date

May 24, 2024

Conditions
Geographic Atrophy
Interventions
DRUG

BI 771716

BI 771716

Trial Locations (9)

16507

Erie Retina Research, LLC, Erie

32204

Florida Retina Institute, Jacksonville

32901

Florida Eye Associates, Melbourne

37215

Tennessee Retina, Nashville

77030

Retina Consultants of Houston, PA-Houston-62050, Houston

77384

Retina Consultants of Texas-The Woodlands-67575, The Woodlands

78750

Austin Clinical Research, LLC, Austin

94598

Bay Area Retina Associates - Walnut Creek, Walnut Creek

97401

Verum Research, LLC, Eugene

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY